Novel therapies in the treatment of systemic lupus erythematosus.
This review highlights the advances made in the use of biological and immunomodulatory agents in systemic lupus erythematosus. Although there have been disappointments (eg, anti-CD40 ligand, DNAse), it is clear that DHEA and mycophenolate mofetil will have a place in the management of the disease. In our opinion, leflunomide and LJP-394 are the most promising therapies currently, under study.
Dequet
C R
CR
Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. dequetc@cshs.org
Wallace
D J
DJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D006801:Humans; D007105:Immune Complex Diseases / Q000517:prevention & control; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D014611:Vaccination
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D001688:Biological Products